Targeting histamine receptor 4 in cholinergic urticaria with izuforant (LEO 152020): results from a phase IIa randomized double-blind placebo-controlled multicentre crossover trial
British Journal of Dermatology · 2024
DOI: 10.1093/bjd/ljae038 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift British Journal of Dermatology, 2024. Verfasst von Eva Grekowitz und 10 weiteren Autor:innen. Beteiligte Einrichtung: Charité - Universitätsmedizin Berlin, Institute of Allergology, Berlin, Germany. Hauptthemen laut MEDLINE: Cross-Over Studies, Receptors, Histamine H4, Chronic Urticaria. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: LEO Pharma, NIH.
Abstract (Originalsprache)
Background
Cholinergic urticaria (CholU) is a common subtype of chronic inducible urticaria, where signs and symptoms (e.g. pruritic wheals and angioedema) are triggered by sweating due to physical exercise, passive warming and by other sweat-inducing situations. While guidelines recommend treatment with second-generation H1 antihistamines, approximately 90% of patients report uncontrolled disease. Targeting the histamine 4 receptor (H4R) has shown promise in preclinical/clinical studies of allergic/inflammatory diseases. Izuforant (LEO 152020) is a selective oral H4R antagonist with expected dual antipruritic and anti-inflammatory effects.
Objectives
To assess the effects of izuforant in adults with CholU, a common type of chronic urticaria driven by histamine and characterized by high skin levels of H4R expression.
Methods
This was a phase IIa randomized double-blind placebo-controlled multicentre crossover trial where patients with CholU with an inadequate response to ≥ 1 standard dose of H1 antihistamine received izuforant 100 mg twice daily or placebo (EUCTR2020-004961-38-DE; NCT04853992). The primary endpoint was change from baseline in Urticaria Activity Score. Exploratory endpoints included CholU activity score over 7 days, urticaria control test, Physician Global Assessment, patient global assessment of severity (PGA-S), provocation tests, Dermatology Life Quality Index and CholU quality of life (CholU-QoL). Pharmacokinetic and pharmacodynamic parameters, and serum biomarkers were assessed, as well as safety and tolerability.
Results
Nineteen patients were randomized and included in the full analysis set; 18 completed treatment [mean (SD) age 29.5 (9.8) years; mean (SD) CholU duration 8.0 (6.3) years]. The primary and most of prespecified exploratory endpoints were not met; there were significant improvements in PGA-S for izuforant vs. placebo (P = 0.02), and nonsignificant improvements for other endpoints in quality of life and histamine skin prick test. All adverse events (AEs) experienced with izuforant were considered mild. The most frequently reported (> 1 patient) were nausea (three patients) and upper abdominal pain (two patients), occurring more frequently with izuforant vs. placebo (one patient each). There were no treatment-related serious AEs and no patient receiving izuforant discontinued the study. Treatment with izuforant did not cause downregulation of H4R.
Conclusions
This is the first study to explore the role of H4R as a therapeutic target in urticaria. Targeting H4R with izuforant was well tolerated but did not demonstrate significant improvements vs. placebo in the primary endpoint and all but one prespecified exploratory endpoint in CholU.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Charité - Universitätsmedizin Berlin, Institute of Allergology, Berlin, Germany.
- Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany.
- Department of Dermatology and Venerology, Kepler University Hospital, Linz, Austria.
- Department of Dermatology, University Allergy Center, University Hospital Carl Gustav Carus, Technical University Dresden, Germany.
- Department of Dermatology and Allergy Biederstein, Technical University of Munich, Faculty of Medicine, Munich, Germany.
- Department of Dermatology, Venereology and Allergy, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
ORCID-Profile: Guido Heine
Förderung
- LEO Pharma
- NIH
Zitieren
APA
Grekowitz, E., Metz, M., Altrichter, S., Bauer, A., Brockow, K., Heine, G., Lionnet, L., Saday, K. K., Hultsch, T., Søerensen, O. E., & Maurer, M. (2024). Targeting histamine receptor 4 in cholinergic urticaria with izuforant (LEO 152020): results from a phase IIa randomized double-blind placebo-controlled multicentre crossover trial. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljae038
Vancouver
Grekowitz E, Metz M, Altrichter S, Bauer A, Brockow K, Heine G, et al. Targeting histamine receptor 4 in cholinergic urticaria with izuforant (LEO 152020): results from a phase IIa randomized double-blind placebo-controlled multicentre crossover trial. British Journal of Dermatology. 2024. doi:10.1093/bjd/ljae038
BibTeX
@article{Grekowitz2024,
author = {Grekowitz, Eva and Metz, Martin and Altrichter, Sabine and Bauer, Andrea and Brockow, Knut and Heine, Guido and Lionnet, Leonard and Saday, Kadriye Kaplan and Hultsch, Thomas and Søerensen, Ole E and Maurer, Marcus},
title = {Targeting histamine receptor 4 in cholinergic urticaria with izuforant (LEO 152020): results from a phase IIa randomized double-blind placebo-controlled multicentre crossover trial},
journal = {British Journal of Dermatology},
year = {2024},
doi = {10.1093/bjd/ljae038}
}
EUVIMED